Lineage Cell Therapeutics, Inc. (LCTX)
LCTXStock
$1.04
-0.0400 (-3.70%) today
At the close, Nov 9, 4:00 PM ET. Pre-market $1.04 -3.70%
- Market cap
- –
- P/E
- –
- EPS, last 4 quarters
- $-0.1900
- Dividend yield
- –
- Day range
- –
- 52-week range
- –
- Average volume
- –
- Previous close
- $1.08
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $5.33, +412.5% from here
Earnings
next estimate $-0.0200Next report Nov 12, 2026
Sep 2025
-550.0%
Dec 2025
+100.0%
Mar 2026
-50.0%
Jun 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $3.68m | $6.61m | $1.73m | $1.07m |
| Gross profit | $3.68m | $6.54m | $1.73m | $1.07m |
| Operating income | -$3.79m | -$6.55m | -$7.59m | -$8.92m |
| Net income | -$29.78m | $851.0k | -$4.81m | $1.48m |
Last four quarters: revenue $13.08m, margin -246.6%, free cash flow -$24.39m
News
8 latest- Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 13, 2026
- Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue EstimatesZacks · Aug 6, 2026
- Lineage Cell Therapeutics (LCTX) Price Target Increased by 14.58% to 5.61Fintel · May 13, 2026
- Guardant Health (GH) Reports Q1 Loss, Beats Revenue EstimatesZacks · May 7, 2026
- Canaccord Genuity Initiates Coverage of Lineage Cell Therapeutics (LCTX) with Buy RecommendationFintel · Apr 28, 2026
- Lineage Cell Therapeutics (LCTX) Price Target Increased by 20.00% to 5.10Fintel · Mar 27, 2026
- Lineage Cell (LCTX) Reports Break-Even Earnings for Q4Zacks · Mar 5, 2026
- Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue EstimatesZacks · Mar 3, 2026
The company
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel allogeneic, or 'off the shelf', cell therapies for serious medical conditions. Lineage's programs are based on its proprietary cell-based technology platform, AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and associated development and manufacturing capabilities. From this proprietary AlloSCOPE platform, Lineage develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or substantially identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages, and in some instances may be designed to have additional beneficial properties.
- Region
- North America
- Website
- lineagecell.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.